Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody
Mahomed, S.; Mkhize, N. N.; Serebryannyy, L. A.; Hermanus, T.; Kgagudi, P.; Kaldine, H.; Lambson, B.; Narpala, S. R.; Basappa, M.; Castro, M.; Lin, B. C.; Carlton, K.; Sands, J. T.; Gall, J. G.; Koup, R. A.; Morris, L.; Abdool Karim, Q.; Moore, P. L.; Abdool Karim, S.; Doria-Rose, N. A.
Show abstract
Monoclonal antibodies (mAbs) are a major class of drugs for treatment and prevention of disease. In early clinical trials, the pharmacokinetics (pK) of mAbs are usually assessed by measuring mAb concentration in serum. However, it is not a given that the mAbs will retain full functionality over time, emphasizing the need for integrated PK and functional assessments. In a re-analysis of data from the CAPRISA 012B trial, a previously published phase 1 study evaluating mAbs CAP256V2LS and VRC07-523LS in HIV-negative women, we report an unexpected disconnect between serum bNAb concentrations and HIV neutralization activity of CAP256V2LS, with implications for ongoing assessment of passive immunization trials.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Temporal Trends And Transmission Dynamics Of Pre-Treatment HIV-1 Drug Resistance Within And Between Risk Groups In Kenya, 1986-2020 91%
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study 90%
- Point-of-care semiquantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate 88%
Similar papers in this journal
- Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity 93%
- Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patients 91%
- Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients 90%
Similar papers in this journal
- People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses 93%
- Virological and serological characterization of critically ill patients with COVID-19 in the UK: a special focus on variant detection 92%
- Frequent development of broadly neutralizing antibodies in early life in a large cohort of HIV-infected children 91%
Similar papers in this journal
- Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial 92%
- Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial 91%
- The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study 90%
Similar papers in this journal
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 91%
- Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV 91%
- COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.